Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype.
The intestinal hormone cholecystokinin (CCK) inhibits food intake via stimulation of vagal afferent neurons (VAN). Recent studies suggest that CCK also regulates the expression of some G protein-coupled receptors and neuropeptide transmitters in these neurons. The aim of the present study was to characterize the expression of cannabinoid (CB)1 receptors in VAN and to determine whether stimulation of these receptors plays a role in regulating neurochemical phenotype. Expression of CB1 in rat VAN was detectable by in situ hybridization or immunohistochemistry after 6 h of fasting and increased to a maximum after 24 h when approximately 50% of neurons in the mid and caudal regions expressed the receptor. Melanin-concentrating hormone (MCH)1 receptors also increased with fasting, but the changes were delayed compared with CB1; in contrast Y2 receptors (Y2R) exhibited reciprocal changes in expression to CB1. Administration of CCK8s (10 nmol ip) to fasted rats decreased expression of CB1 with a t(1/2) of approximately 1 h compared with 3 h for MCH1. The action of CCK8s was inhibited by ghrelin and orexin-A. The CB1 agonist anandamide (intraperitoneally) reversed the effect of CCK8s on CB1, MCH1, and Y2 receptor expression. In contrast, in rats fasted for 18 h, administration of a CB1 antagonist/inverse agonist (AM281 ip) downregulated CB1 expression and increased Y2 receptor expression. Activation of vagal CB1 receptors therefore influences the neurochemical phenotype of these neurons, indicating a new and hitherto unrecognized role for endocannabinoids in gut-brain signaling.
Burdyga
Galina
G
Physiological Laboratory, School of Biomedical Sciences, Univ. of Liverpool, Liverpool, L69 3BX, UK.
Varro
Andrea
A
Dimaline
Rod
R
Thompson
David G
DG
Dockray
Graham J
GJ
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D054314:Drug Inverse Agonism; D004435:Eating; D063388:Endocannabinoids; D005508:Food Deprivation; D054439:Ghrelin / Q000378:metabolism; D006207:Half-Life; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D007274:Injections, Intraperitoneal; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D007700:Kinetics; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D009475:Neurons, Afferent / Q000378:metabolism*; D009479:Neuropeptides / Q000378:metabolism; D009620:Nodose Ganglion / Q000378:metabolism*; D000068797:Orexins; D010641:Phenotype; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D017476:Receptors, Neuropeptide Y / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000378:metabolism; D012844:Sincalide / Q000008:administration & dosage / Q000378:metabolism*
D001095:Arachidonic Acids; D063388:Endocannabinoids; D054439:Ghrelin; D047908:Intracellular Signaling Peptides and Proteins; C491208:MCHR1 protein, rat; D009025:Morpholines; D009479:Neuropeptides; D000068797:Orexins; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D017476:Receptors, Neuropeptide Y; D017481:Receptors, Somatostatin; D012844:Sincalide; C109925:AM 281; C078814:anandamide